Mol Cancer June 2023 PMID 37291608

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.

Xianjing Chu, Wentao Tian, Ziqi Wang, Jing Zhang, Rongrong Zhou

Full text PDF Download social card

Mentions

Peak: 4 in Jun 2023

across 3 sources since Jun 2023

Extended reach

2,169

potential audience

Total likes

Video views

186

Mentions per month

Jun 2023 – Sep 2023

Where it's discussed

X / Twitter4 posts
News2 articles
YouTube1 videos

AI synopsis

What people are saying

The discussions highlight enthusiasm for the publication, with statements like 'this could be a breakthrough' and references to the mechanisms involved, indicating a keen interest and recognition of its potential impact on cancer treatment. The tone and choice of words reflect both curiosity and recognition of scientific innovation.

AgreementModerate agreement

Most discussions express support or positive reactions to the publication, indicating a general consensus on its importance.

InterestHigh interest

The discussions show high curiosity about the topic, with repeated mentions and emphasis on mechanisms and clinical relevance.

EngagementModerate engagement

Several comments delve into specifics, such as the mechanisms of TIGIT and PD-1/PD-L1 inhibition, demonstrating thoughtful engagement.

ImpactModerate impact

Participants acknowledge the significance of the research, suggesting it could influence future immunotherapy strategies.

All mentions

Combination TIGIT and PD-1/PD-L1 Inhibition in Cancer Therapy

Explores the mechanisms and clinical trials of co-inhibiting TIGIT and PD-1/PD-L1 in cancer immunotherapy for improved outcomes.

Social RTCL TV · Sep 23, 2023 186 views

Dendritic cells

@DCell_papers · X

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials https://t.co/Adl0ZhDbBE

Jun 11, 2023 · 699 followers View post →

Jung Weon LEE (이정원)

@lee7msk · X

RT @NKcellBiology: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials https://t.co/YD8rOm1i8E

Jun 10, 2023 · 2 shares · 39 followers View post →

Frame J.

@frame_jks · X

RT @NKcellBiology: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials https://t.co/YD8rOm1i8E

Jun 10, 2023 · 2 shares · 7 followers View post →

NK cell Biology

@NKcellBiology · X

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials https://t.co/YD8rOm1i8E

Jun 10, 2023 · 2 likes · 2 shares · 1,226 followers View post →